BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lopes-Pacheco M, Pedemonte N, Veit G. Discovery of CFTR modulators for the treatment of cystic fibrosis. Expert Opin Drug Discov 2021;16:897-913. [PMID: 33823716 DOI: 10.1080/17460441.2021.1912732] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Lewis T, Wade KC, Davis JM. Challenges and opportunities for improving access to approved neonatal drugs and devices. J Perinatol. [DOI: 10.1038/s41372-021-01304-2] [Reference Citation Analysis]
2 Centorame A, Dumut DC, Youssef M, Ondra M, Kianicka I, Shah J, Paun RA, Ozdian T, Hanrahan JW, Gusev E, Petrof B, Hajduch M, Pislariu R, De Sanctis JB, Radzioch D. Treatment With LAU-7b Complements CFTR Modulator Therapy by Improving Lung Physiology and Normalizing Lipid Imbalance Associated With CF Lung Disease. Front Pharmacol 2022;13:876842. [DOI: 10.3389/fphar.2022.876842] [Reference Citation Analysis]
3 Matos AM, Jordan P, Matos P. Treatment of Polarized Cystic Fibrosis Airway Cells With HGF Prevents VX-661-Rescued F508del-CFTR Destabilization Caused by Prolonged Co-exposure to VX-770. Front Mol Biosci 2021;8:812101. [PMID: 35004859 DOI: 10.3389/fmolb.2021.812101] [Reference Citation Analysis]
4 Pinto MC, Silva IAL, Figueira MF, Amaral MD, Lopes-Pacheco M. Pharmacological Modulation of Ion Channels for the Treatment of Cystic Fibrosis. J Exp Pharmacol 2021;13:693-723. [PMID: 34326672 DOI: 10.2147/JEP.S255377] [Reference Citation Analysis]
5 King JA, Nichols A, Bentley S, Carr SB, Davies JC. An Update on CFTR Modulators as New Therapies for Cystic Fibrosis. Pediatr Drugs. [DOI: 10.1007/s40272-022-00509-y] [Reference Citation Analysis]
6 Ribeiro CMP, Gentzsch M. Impact of Airway Inflammation on the Efficacy of CFTR Modulators. Cells 2021;10:3260. [PMID: 34831482 DOI: 10.3390/cells10113260] [Reference Citation Analysis]
7 Erdem R, Ambler G, Al-Ibrahim M, Fraczek K, Dong SD, Gast C, Mercer LD, Raine M, Tennant SM, Chen WH, de Hostos EL, Choy RKM. A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model. PLoS Negl Trop Dis 2021;15:e0009969. [PMID: 34793441 DOI: 10.1371/journal.pntd.0009969] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Veit G, Velkov T, Xu H, Vadeboncoeur N, Bilodeau L, Matouk E, Lukacs GL. A Precision Medicine Approach to Optimize Modulator Therapy for Rare CFTR Folding Mutants. J Pers Med 2021;11:643. [PMID: 34357110 DOI: 10.3390/jpm11070643] [Reference Citation Analysis]
9 Ciciriello F, Bijvelds MJC, Alghisi F, Meijsen KF, Cristiani L, Sorio C, Melotti P, Fiocchi AG, Lucidi V, De Jonge HR. Theratyping of the Rare CFTR Variants E193K and R334W in Rectal Organoid-Derived Epithelial Monolayers. JPM 2022;12:632. [DOI: 10.3390/jpm12040632] [Reference Citation Analysis]